[Featured Stock] Myungmoon Pharmaceutical Rises on Production of Treatment Similar to Remdesivir 600 Times 'Nafamostat'
Active Ingredient 'Camostat' in Myungmoon Pharmaceutical CNP Tablets
Known for Efficacy Similar to Nafamostat, 600 Times Superior to Remdesivir
[Asia Economy Reporter Minwoo Lee] Myungmoon Pharmaceutical's stock price is on the rise. The news that the company is producing a product potentially superior to existing COVID-19 treatment candidates appears to have acted as a positive factor.
As of 11:05 AM on the 15th, Myungmoon Pharmaceutical's stock price is up 9.0% from the previous day, trading at 5,550 KRW. The spotlight seems to be on the production of C&P tablets, which contain camostat mesylate, known to be effective in inhibiting the COVID-19 virus.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Earlier, the Korea Pasteur Institute announced research results showing that nafamostat mesylate, an anticoagulant and acute pancreatitis treatment ingredient, demonstrated over 600 times greater efficacy against the COVID-19 virus compared to remdesivir, a treatment candidate that received emergency use authorization in the United States. Since camostat mesylate is known to exhibit similar effects, investor expectations have once again focused on Myungmoon Pharmaceutical's C&P tablets.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
